Clinical characteristics and hematologic responses to Imatinib in patients with chronic phase myeloid leukemia (CML) at Cipto Mangunkusumo Hospital.

Keyphrases

• Clinical Characteristics 100%
• Chronic Myeloid Leukemia 100%
• Imatinib 100%
• Characteristic Response 100%
• Hematological Response 100%
• Chronic Phase 75%
• Complete Hematologic Response 75%
• Overall Survival 50%
• Philadelphia Chromosome 50%
• BCR-ABL Positive 50%
• White Cell Count 50%
• Nausea 25%
• Anemia 25%
• Adverse Events 25%
• Medical Records 25%
• Patient Characteristics 25%
• Spleen 25%
• Complete Blood Count 25%
• Hemoglobin Level 25%
• National Hospital 25%
• Polyclinic 25%
• Previous Treatment 25%
• Platelet Count 25%
• Thrombocytopenia 25%
• Laboratory Features 25%
• Internal Medicine 25%
• Patient Survival 25%
• Bone Marrow 25%
• Neutropenia 25%
• Differential Cell Count 25%
• Myalgia 25%
• Hydroxyurea 25%
• Hypopigmentation 25%
• Splenomegaly 25%
• Basophils 25%
• Non-culprit Lesion 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Imatinib 100%
• Myeloid Leukemia 100%
• Overall Survival 50%
• Philadelphia 1 Chromosome 50%
• Cross-Sectional Study 25%
• Anemia 25%
• Adverse Event 25%
• Nausea 25%
• Thrombocytopenia 25%
• Neutropenia 25%
• Hydroxycarbamide 25%
• Myalgia 25%
• Splenomegaly 25%
• Hypopigmentation 25%

Biochemistry, Genetics and Molecular Biology

• Myeloid 100%
• Imatinib 100%
• Overall Survival 50%
• Philadelphia Chromosome 50%
• Leukocyte Count 50%
• Cross Sectional Study 25%
• Medical Record 25%
• Platelet Count 25%
• Thrombocytopenia 25%
• Hemoglobin Blood Level 25%
• Blood Cell Count 25%
• Hydroxycarbamide 25%